Market Overview

UPDATE: Jefferies Upgrades Pfizer from Hold to Buy, Boosts Target to $38

Share:
Related PFE
Is The Dollar Really As Strong As Companies Are Suggesting?
Was It Foreseeable For Pfizer To Lower Its 2015 Guidance?
$CTIX - Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon (Seeking Alpha)

Pfizer (NYSE: PFE) has received an upgraded rating from Hold to Buy and a raised price target from $33 to $38 at Jefferies Tuesday morning.

Pfizer's upgrades follows acknowledgments that Oncology and restructuring are key themes for the Pharma sector and Pfizer has both of those covered with palbociclib looking like it could launch before year end, according to the firm's Jeffery Holland.

The Jefferies analyst expects the market to soon be reflecting incremental value in the shares based on the drivers above, adding significant upside to the companies shares.

Shares of Pfizer are up 2.7 percent to $31.42 at last check following the upgrade.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2014Deutsche BankMaintainsBuy
Oct 2014JefferiesMaintainsBuy
Aug 2014Deutsche BankInitiates Coverage onBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters